NorthStrive Biosciences Grants Exclusive Worldwide License for EL-22 and EL-32 Animal Health Probiotics
NorthStrive Biosciences executed an exclusive, worldwide (ex-Korea) license agreement with Modulant Biosciences for its EL-22 and EL-32 myostatin-engineered probiotics in non-human animal health, including feed additives. Modulant assumes all development, manufacturing, regulatory and commercialization costs in exchange for royalty-bearing sublicensable rights.
1. Definitive License Agreement Terms
NorthStrive Biosciences and Modulant Biosciences signed a binding, exclusive license covering EL-22 and EL-32 for non-human animal health use worldwide, excluding the Republic of Korea. The agreement grants Modulant royalty-bearing, sublicensable rights and converts a May 2025 term sheet into a definitive contract.
2. Asset Profiles and Market Opportunity
EL-22 and EL-32 leverage proprietary myostatin and activin-A pathway technology to enhance muscle development, strength and feed efficiency in livestock and companion animals. These assets target a growing global market for animal health and nutrition products aimed at improving performance, wellness and longevity.
3. Development, Commercialization and Risks
Modulant bears full responsibility for development, manufacturing, regulatory submissions and commercialization under the license, using commercially reasonable efforts. While the agreement enables focused advancement, successful product approval, market acceptance and revenue generation remain uncertain.